Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Fibroblast growth factor (FGF) 21 is associated with hepatic inflammation and fibrosis. However, little is known regarding the effects of inflammation and fibrosis on the β-Klotho and FGF21 pathway in the liver. Methods: Enrolled patients had biopsy-confirmed viral or alcoholic hepatitis. FGF19, FGF21 and β-Klotho levels were evaluated using enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and Western blotting. Furthermore, we explored the underlying mechanisms for this process by evaluating nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathway involvement in Huh-7 cells. Results: We observed that the FGF19 and FGF21 serum and mRNA levels in the biopsied liver tissue gradually increased and were correlated with fibrosis stage. Inflammatory markers (interleukin 1β [IL-1β], IL-6, and tumor necrosis factor-α) were positively correlated, while β-Klotho expression was negatively correlated with the degree of fibrosis. In Huh-7 cells, IL-1β increased FGF21 levels and decreased β-Klotho levels. NF-κB and JNK inhibitors abolished the effect of IL-1β on both FGF21 and β-Klotho expression. FGF21 protected IL-1β-induced growth retardation in Huh-7 cells. Conclusions: These results indicate that the inflammatory response during fibrogenesis increases FGF21 levels and suppresses β-Klotho via the NF-κB and JNK pathway. In addition, FGF21 likely protects hepatocytes from hepatic inflammation and fibrosis.
Abstract
Background/Aims: Fibroblast growth factor (FGF) 21 is associated with hepatic inflammation and fibrosis. However, little is known regarding the effects of inflammation and fibrosis on the β-Klotho and FGF21 pathway in the liver. Methods: Enrolled patients had biopsy-confirmed viral or alcoholic hepatitis. FGF19, FGF21 and β-Klotho levels were evaluated using enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and Western blotting. Furthermore, we explored the underlying mechanisms for this process by evaluating nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathway involvement in Huh-7 cells. Results: We observed that the FGF19 and FGF21 serum and mRNA levels in the biopsied liver tissue gradually increased and were correlated with fibrosis stage. Inflammatory markers (interleukin 1β [IL-1β], IL-6, and tumor necrosis factor-α) were positively correlated, while β-Klotho expression was negatively correlated with the degree of fibrosis. In Huh-7 cells, IL-1β increased FGF21 levels and decreased β-Klotho levels. NF-κB and JNK inhibitors abolished the effect of IL-1β on both FGF21 and β-Klotho expression. FGF21 protected IL-1β-induced growth retardation in Huh-7 cells. Conclusions: These results indicate that the inflammatory response during fibrogenesis increases FGF21 levels and suppresses β-Klotho via the NF-κB and JNK pathway. In addition, FGF21 likely protects hepatocytes from hepatic inflammation and fibrosis.
참고문헌 (37)
- Goetz R, "Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members", Mol Cell Biol, 27, pp.3417~3428 (2007)[DOI]
- Beenken A, "The FGF family: biology, pathophysiology and therapy", Nat Rev Drug Discov, 8, pp.235~253 (2009)[DOI]
- Potthoff MJ, "Endocrine fibroblast growth factors 15", 19 and 21: from feast to famine, 2012, pp.26, 312~324
- Kurosu H, "Endocrine fibroblast growth factors as regulators of metabolic homeostasis", Biofactors, 35, pp.52~60 (2009)[DOI]
- Lin BC, "Liver-specific activities of FGF19 require Klotho beta", J Biol Chem, 282, pp.27277~27284 (2007)[DOI]
- Kurosu H, "Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21", J Biol Chem, 282, pp.26687~26695 (2007)[DOI]
- Kharitonenkov A, "FGF-21", FGF-21 receptor interaction and activation is determined by betaKlotho, 2008, pp.215, 1~7
- Ogawa Y, "BetaKlotho is required for metabolic activity of fibroblast growth factor 21", Proc Natl Acad Sci U S A, 104, pp.7432~7437 (2007)[DOI]
- Fukumoto S, "Actions and mode of actions of FGF19 subfamily members", Endocr J, 55, pp.23~31 (2008)[DOI]
- Schaap FG, "High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis", Hepatology, 49, pp.1228~1235 (2009)[DOI]
- Hyeon J, "Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma", Dig Dis Sci, 58, pp.1916~1922 (2013)[DOI]
- Fon Tacer K, "Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse", Mol Endocrinol, 24, pp.2050~2064 (2010)[DOI]
- Liu WY, "The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target", Expert Opin Ther Targets, 18, pp.1305~1313 (2014)[DOI]
- Wu C, "Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking", Hepatology, 54, pp.1966~1974 (2011)[DOI]
- Yang C, "Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress", BMC Gastroenterol, 13, pp.67~ (2013)[DOI]
- Seki E, "Hepatic inflammation and fibrosis: functional links and key pathways", Hepatology, 61, pp.1066~1079 (2015)[DOI]
- 엄영우, "Mesenchymal stem cell therapy for liver fibrosis", The Korean Journal of Internal Medicine, 30(5), pp.580~589 (2015), 대한내과학회[DOI]
- 김가은, "Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis", Clinical and Molecular Hepatology, 23(1), pp.34~41 (2017), 대한간학회[DOI]
- 김가은, "Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis", Gut and Liver, 11(1), pp.93~101 (2017), 거트앤리버 소화기연관학회협의회
- Luedde T, "NF-kappaB in the liver: linking injury, fibrosis and hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 8, pp.108~118 (2011)[DOI]
- Gao B, "Alcoholic liver disease: pathogenesis and new therapeutic targets", Gastroenterology, 141, pp.1572~1585 (2011)[DOI]
- Suk KT, "Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial", Hepatology, 64, pp.2185~2197 (2016)[DOI]
- Kim G, "Relative adrenal insufficiency in patients with cirrhosis: a systematic review and meta-analysis", Dig Dis Sci, 62, pp.1067~1079 (2017)[DOI]
- Langhans B, "Intrahepatic IL-8 producing <TEX>$Foxp3^{+}CD4^{+}$<", TEX> regulatory T cells and fibrogenesis in chronic hepatitis C, 2013, pp.59, 229~235
- Zhao J, "Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment", Hepatology, 59, pp.1331~1342 (2014)[DOI]
- Jeong WI, "Abrogation of the antifibrotic effects of natural killer cells", interferon-gamma contributes to alcohol acceleration of liver fibrosis, 2008, pp.134, 248~258
- Zhao Y, "IL-1beta inhibits beta-Klotho expression and FGF19 signaling in hepatocytes", Am J Physiol Endocrinol Metab, 310, pp.E289~E300 (2016)[DOI]
- Diaz-Delfin J, "TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway", Endocrinology, 153, pp.4238~4245 (2012)[DOI]
- Zhou M, "Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice", Hepatology, 63, pp.914~929 (2016)[DOI]
- Gariani K, "Increased FGF21 plasma levels in humans with sepsis and SIRS", Endocr Connect, 2, pp.146~153 (2013)[DOI]
- Feingold KR, "FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob", ob mice from the toxicity of sepsis, 2012, pp.153, 2689~2700
- Rusli F, "Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL", 6J mice, 2016, pp.6, 30484~
- Gieling RG, "Interleukin-1 participates in the progression from liver injury to fibrosis", Am J Physiol Gastrointest Liver Physiol, 296, pp.G1324~G1331 (2009)[DOI]
- Petrasek J, "IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice", J Clin Invest, 122, pp.3476~3489 (2012)[DOI]
- Luedde T, "Cell death and cell death responses in liver disease: mechanisms and clinical relevance", Gastroenterology, 147, pp.765~783 (2014)[DOI]
- Seki E, "A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches", Gastroenterology, 143, pp.307~320 (2012)[DOI]
- Weber A, "Interleukin-1 (IL-1) pathway", Sci Signal, 3 (2010)